Biochemical Markers Predict Risk of Incident Diabetes
By LabMedica International staff writers Posted on 22 Aug 2018 |
Image: A C-telopeptide of type 1 collagen (CTX) assay kit (Photo courtesy of Wako Chemicals).
Low osteocalcin and C-telopeptide of type 1 collagen levels in postmenopausal women are associated with an increased risk for insulin resistance and incident diabetes.
A recent study investigated the relationship of osteocalcin (OC), which is a marker of bone formation, and C-telopeptide of type I collagen (CTX), which a marker of bone resorption, with incident diabetes in older women.
A multi-institute team of scientists led by those at the Albert Einstein College of Medicine and Montefiore Medical Center (Bronx, NY, USA) analyzed 1,455 female participants from the population-based Cardiovascular Health Study (mean age 74.6 ± 5.0 years). The cross-sectional association of serum total OC and CTX levels with insulin resistance (HOMA-IR) was examined using multiple linear regressions. The longitudinal association of both markers with incident diabetes, defined by follow-up glucose measurements, medications, and ICD-9 codes, was examined using multivariable Cox proportional hazards models.
The investigators reported that continuous levels of osteocalcin were significantly inversely related to insulin resistance. Continuous C-telopeptide of type 1 collagen levels, though marginally insignificant, showed a similar relationship to insulin resistance. At median follow-up of 11.5 years, 196 cases of incident diabetes were discovered among the participants. After adjustment, both biomarkers still showed inverse associations with incident diabetes (osteocalcin: hazard ratio 0.85 per SD); C-telopeptide of type 1 collagen: hazard ratio 0.82 per SD).
The authors concluded that osteocalcin and C-telopeptide of type 1 collagen are strongly associated with insulin resistance and incident diabetes in late postmenopausal women. The findings also suggest that bone health may be a factor in glucose maintenance in the same postmenopausal demographic. The study was published in the August 2018 issue of the journal Diabetes Care.
Related Links:
Albert Einstein College of Medicine
A recent study investigated the relationship of osteocalcin (OC), which is a marker of bone formation, and C-telopeptide of type I collagen (CTX), which a marker of bone resorption, with incident diabetes in older women.
A multi-institute team of scientists led by those at the Albert Einstein College of Medicine and Montefiore Medical Center (Bronx, NY, USA) analyzed 1,455 female participants from the population-based Cardiovascular Health Study (mean age 74.6 ± 5.0 years). The cross-sectional association of serum total OC and CTX levels with insulin resistance (HOMA-IR) was examined using multiple linear regressions. The longitudinal association of both markers with incident diabetes, defined by follow-up glucose measurements, medications, and ICD-9 codes, was examined using multivariable Cox proportional hazards models.
The investigators reported that continuous levels of osteocalcin were significantly inversely related to insulin resistance. Continuous C-telopeptide of type 1 collagen levels, though marginally insignificant, showed a similar relationship to insulin resistance. At median follow-up of 11.5 years, 196 cases of incident diabetes were discovered among the participants. After adjustment, both biomarkers still showed inverse associations with incident diabetes (osteocalcin: hazard ratio 0.85 per SD); C-telopeptide of type 1 collagen: hazard ratio 0.82 per SD).
The authors concluded that osteocalcin and C-telopeptide of type 1 collagen are strongly associated with insulin resistance and incident diabetes in late postmenopausal women. The findings also suggest that bone health may be a factor in glucose maintenance in the same postmenopausal demographic. The study was published in the August 2018 issue of the journal Diabetes Care.
Related Links:
Albert Einstein College of Medicine
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms